Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify

 

Abstract

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated the single drug potency of Pirfenidone, an approved drug for the treatment of lung fibrosis. Five human lung cancer cell lines and one murine line were investigated for transforming growth factor beta inhibition via Pirfenidone by using flow cytometry, In-Cell western analysis, proliferation assays as well as comprehensive analyses of the transcriptome with subsequent bioinformatics analysis. Overall, Pirfenidone induced cell cycle arrest, down-regulated SMAD expression and reduced proliferation in lung cancer. Furthermore, cell stress pathways and pro-apoptotic signaling may be mediated by reduced expression of Survivin. A murine subcutaneous model was used to assess the in vivo drug efficacy of Pirfenidone and showed reduced tumor growth and increased infiltration of T cells and NK cells. This data warrant further clinical evaluation of Pirfenidone with advanced non-small cell lung cancer. The observed in vitro and in vivo effects point to a substantial benefit for using Pirfenidone to reactivate the local immune response and possible application in conjunction with current immunotherapies.

PMID: 32039023 [PubMed]

16:13

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:13

In reply to this message

pubmed: caandvteortroorpul

End of an era for erythropoiesis stimulating agents in oncology.

Related Articles

End of an era for erythropoiesis stimulating agents in oncology.

Int J Cancer. 2020 Feb 09;:

Authors: Schoen MW, Hoque S, Witherspoon BJ, Schooley B, Sartor O, Yang AT, Yarnold PR, Knopf KB, Hrushesky WR, Dickson M, Chen BJ, Nabhan C, Bennett CL

Abstract

Erythropoiesis stimulating agents (ESAs) are available to treat chemotherapy-induced anemia (CIA). In 2007-2008, regulatory notifications advised of venous thromboembolism and mortality risks while the Center for Medicare and Medicaid Services' restricted ESA initiation to patients with hemoglobin <10

PMID: 32037527 [PubMed - as supplied by publisher]

16:13

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:13

In reply to this message

pubmed: caandvteortroorpul

Elevated D-Dimer Combined with Persistent Acupuncture-like Chest Pain in An Elderly Patient Misdiagnosed as Pulmonary Embolism Finally Proved as Lung Hamartoma with Secondary Lung Infection by Bronchoscopy Biopsy: a Case Report and Literature Review.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.clin-lab-publications.com-assets-PubMed.png Related Articles

Elevated D-Dimer Combined with Persistent Acupuncture-like Chest Pain in An Elderly Patient Misdiagnosed as Pulmonary Embolism Finally Proved as Lung Hamartoma with Secondary Lung Infection by Bronchoscopy Biopsy: a Case Report and Literature Review.

Clin Lab. 2019 Sep 01;65(9):

Authors: Chen Y, Li LQ, Wang MH, Li WQ, Zhang Q, Zhang HF, Ge YL